Black Diamond Therapeutics Inc (NASDAQ: BDTX) on Monday, soared 3.46% from the previous trading day, before settling in for the closing price of $2.31. Within the past 52 weeks, BDTX’s price has moved between $1.20 and $6.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 88.39%. With a float of $43.30 million, this company’s outstanding shares have now reached $56.68 million.
The extent of productivity of a business whose workforce counts for 24 workers is very important to gauge. In terms of profitability, gross margin is 99.75%, operating margin of -5.72%, and the pretax margin is 7.27%.
Black Diamond Therapeutics Inc (BDTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Black Diamond Therapeutics Inc is 23.86%, while institutional ownership is 62.07%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 88.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.33% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Black Diamond Therapeutics Inc (BDTX) is currently performing well based on its current performance indicators. A quick ratio of 9.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.06, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.02 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
The latest stats from [Black Diamond Therapeutics Inc, BDTX] show that its last 5-days average volume of 0.97 million was inferior to 2.34 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 28.39%. Additionally, its Average True Range was 0.17.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 73.46%, which indicates a significant increase from 59.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.11% in the past 14 days, which was lower than the 78.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.87, while its 200-day Moving Average is $2.64. Now, the first resistance to watch is $2.48. This is followed by the second major resistance level at $2.56. The third major resistance level sits at $2.69. If the price goes on to break the first support level at $2.27, it is likely to go to the next support level at $2.14. Assuming the price breaks the second support level, the third support level stands at $2.06.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
Market capitalization of the company is 135.90 million based on 56,863K outstanding shares. Right now, sales total 0 K and income totals -69,680 K. The company made 70,000 K in profit during its latest quarter, and 56,540 K in sales during its previous quarter.
